2. Рузиева С.Х. Дерматологические проявления эндокринных заболеваний. Вестник современных исследований. 2018; 6.1: 85–90. [Ruzieva S.Kh. Dermatological manifestations of endocrine diseases. Vestnik sovremennyh issledovaniy = Bulletin of Modern Studies. 2018; 6.1: 85–90 (In Russ.)]. EDN: UVIRIO.

3. Gonzalez-Ramos J., Lamas C., Bellon T. et al. Oseltamivir-induced toxic epidermal necrolysis in a patient with Cushing’s disease. Indian J Dermatol Venereol Leprol. 2020; 86(5): 515–18. https://dx.doi.org/10.4103/ijdvl.IJDVL_53_18.

4. Кузнецов Е.В., Жукова Л.А., Пахомова Е.А., Гуламов А.А. Эндокринные заболевания как медико-социальная проблема. Современные проблемы науки и образования. 2017; 4: 62. [Kuznetsov E.V., Zhukova L.A., Pakhomova E.A., Gulamov A.A. Endocrine diseases as a medical and social problem. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education. 2017; 4: 62 (In Russ.)]. EDN: YTHNOD.

5. Потекаев Н.Н., Жуковский Р.О., Шнахова Л.М., Тихомолова М.М. Acanthosis nigricans. Клиническая дерматология и венерология. 2011; 9(2): 36–38. [Potekaev N.N., Zhukovsky R.O., Shnakhova L.M., Tikhomolova M.M. Acantosis nigricans. Klinicheskaya dermatologiya i venerologiya = Russian Journal of Clinical Dermatology and Venereology. 2011; 9(2): 36–38 (In Russ.)]. EDN: QAAOOZ.

6. Hines A., Alavi A., Davis M.D.P. Cutaneous manifestations of diabetes. Med Clin North Am. 2021; 105(4): 681–97. https://dx.doi.org/10.1016/j.mcna.2021.04.008.

7. Coerdt K.M., Zolper E.G., Starr A.G. et al. Cutaneous mucormycosis of the lower extremity leading amputation in two diabetic patients. Arch Plast Surg. 2021;4 8(2): 231–36. https://dx.doi.org/10.5999/aps.2020.00549.

8. García-Arpal M., Bujalance-Cabrera C., Banegas-Illescas M.E. et al. Scleredema diabeticorum in a patient: Un uncommon etiology of restrictive lung pattern Escleredema diabeticorum en un paciente: una etiología infrecuente de patron restrictivo pulmonar. Dermatol Online J. 2021; 27(3): 13030/qt71g4k3qf.

9. Потекаев Н.Н., Круглова Л.С., Федотова К.Ю. с соавт. Красный плоский лишай в составе синдромов: случаи из практики. Клиническая дерматология и венерология. 2016; 15(3): 17–23. [Potekaev N.N., Kruglova L.S., Fedotova K.Yu. et al. Lichen planus as a part of syndromes: case studies. Klinicheskaya dermatologiya i venerologiya = Russian Journal of Clinical Dermatology and Venereology. 2016; 15(3): 17–23(in Russ.)]. https://dx.doi.org/10.17116/klinderma201615317-23. EDN: WEFESB.

10. Kokten N., Uzun L., Karadag A.S. et al. Grinspan’s syndrome: A rare case with malignant transformation. Case Rep Otolaryngol. 2018; 2018: 9427650. https://dx.doi.org/10.1155/2018/9427650.

11. Otero-Rey E.M., Suarez-Alen F., Penamaria-Mallon M. et al. Malignant transformation of oral lichen planus by a chronic inflammatory process. Use of topical corticosteroids to prevent this progression? Acta Odontologica Scandinavica. 2014; 72(8): 570–77. https://dx.doi.org/10.3109/00016357.2014.914570.

12. Лыкова С.Г., Моржанаева М.А., Немчанинова О.Б., Свечникова Е.В. Псориаз у пациентов с метаболическим синдромом: клинические аспекты проблемы. Клиническая дерматология и венерология. 2020; 19(2): 214–222. [Lykova S.G., Morzhanaeva M.A., Nemchaninova O.B., Svechnikova E.V. Psoriasis in patients with metabolic syndrome: clinical aspects of the problem. Klinicheskaya dermatologiya i venerologiya = Russian Journal of Clinical Dermatology and Venereology. 2020; 19(2): 214–222 (In Russ.)]. https://dx.doi.org/10.17116/klinderma202019021214. EDN: YEFINL.

13. Свечникова Е.В., Спицына А.В., Немчанинова О.Б. с соавт. Общие генетические аспекты псориаза и сахарного диабета 2-го типа. Медицинский альманах. 2018; 3: 124–127. [Svechnikova E.V., Spitsyna A.V., Nemchaninova O.B. et al. General genetic aspects of psoriasis and type 2 diabetes mellitus. Meditsinskiy al’manakh = Medical Almanac. 2018; 3: 124–127 (In Russ.)]. EDN: XNKCDZ.

14. Уфимцева М.А., Попов А.А., Федотова Л.В. с соавт. Псориаз и метаболический синдром: обзор литературы. Ожирение и метаболизм. 2020; 17(4): 369–374. [Ufimtseva M.A., Popov A.A., Fedotova L.V. et al. Psoriasis and metabolic syndrome: A review. Ozhirenie i metabolism = Obesity and Metabolism. 2020; 17(4): 369–374 (In Russ.)]. https://dx.doi.org/10.14341/omet12517. EDN: RNBJRQ

15. Naik P.P., Farrukh S.N. Clinical significance of diabetic dermatopathy. Diabetes Metab Syndr Obes. 2020; 13: 4823–27. https://dx.doi.org/10.2147/DMSO.S286887.

16. Штода Ю.М., Слесаренко Н.А., Родионова Т.И. с соавт. Дерматологические проявления сахарного диабета. Современные проблемы науки и образования. 2014; 2: 371. [Shtoda Yu.M., Slesarenko N.A., Rodionova T.I. et al. Dermatological manifestations of diabetes mellitus. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education. 2014; 2: 371 (In Russ.)]. EDN: SBWHUB.

17. Baccarani A., De Maria F., Pappalardo M. et al. Necrobiosis lipoidica affecting the leg: What is the best treatment in a patient with very high aesthetic demand? Plast Reconstr Surg Glob Open. 2020; 8(7): e3000. https://dx.doi.org/10.1097/GOX.0000000000003000.

18. Смирнова О.М., Кононенко И.В., Пряхина К.Ю., Нагаева К.Н. Липоидный некробиоз и другие поражения кожи при сахарном диабете. Сахарный диабет. 2007; 10(2): 71–74. [Smirnova O.M., Kononenko I.V., Pryakhina K.Yu., Nagaeva K.N. Lipoid necrobiosis and other skin lesions in diabetes mellitus. Saharnyj diabet = Diabetes Mellitus. 2007; 10(2): 71–74 (In Russ.)]. https://dx.doi.org/10.14341/2072-0351-5801. EDN: IAXLHP.

19. Штода Ю.М., Слесаренко Н.А., Родионова Т.И. с соавт. Дерматологические проявления сахарного диабета. Современные проблемы науки и образования. 2014; 2: 371. [Shtoda Yu.M., Slesarenko N.A., Rodionova T.I. et al. Dermatological manifestations of diabetes mellitus. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education. 2014; 2: 371 (In Russ.)]. EDN: SBWHUB.

20. Ketterer R., Frenk E. [Skin changes in endocrine disorders (with the exception of diabetes). Ther Umsch. 1995; 52(4): 269–74 (In German)].

21. Domingos A., Calcas R., Carias E. et ak. Acquired perforating dermatosis with associated complicated cellulitis and amputation in a hemodialysis patient. Clin Nephrol Case Stud. 2021; 9: 33–38. https://dx.doi.org/10.5414/CNCS110297/

22. Wang M.F., Mei X.L., Wang L., Lin-Feng L. Clinical characteristics and prognosis of acquired perforating dermatosis: A case report. Exp Ther Med. 2020; 19(6): 3634–40. https://dx.doi.org/10.3892/etm.2020.8651.

23. Sanches M.M., Roda A., Pimenta R. et al. Cutaneous manifestations of diabetes mellitus and prediabetes. Acta Med Port. 2019; 32(6): 459–65. https://dx.doi.org/10.20344/amp.10738

24. Svoboda S.A., Shields B.E. Cutaneous manifestations of nutritional excess: Pathophysiologic effects of hyperglycemia and hyperinsulinemia on the skin. Cutis. 2021; 107(2): 74–78. https://dx.doi.org/10.12788/cutis.0173.

25. Julka S., Jamdagni N., Verma S., Goyal R. Yellow palms and soles: A rare skin manifestation in diabetes mellitus. Indian J Endocrinol Metab. 2013; 17(Suppl 1): S299–300. https://dx.doi.org/10.4103/2230-8210.119625.

26. Trihan J.E., Laneelle D., Metcalfe N. et al. Diabetes-associated dermatological manifestations in primary care and their association with vascular complications. J Diabetes Metab Disord. 2020; 19(2): 989–96. https://dx.doi.org/10.1007/s40200-020-00594-1.

27. Taylor P.N., Albrecht D., Scholz A. et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018; 14(5): 301–16. https://doi: 10.1038/nrendo.2018.18.

28. Chaker L., Bianco A.C., Jonklaas J., Peeters R.P. Hypothyroidism. Lancet. 2017; 390(10101): 1550–62. https://dx.doi.org/10.1016/S0140-6736(17)30703-1.

29. Redford C., Vaidya B. Subclinical hypothyroidism: Should we treat? Post Reprod Health. 2017; 23(2): 55–62. https://dx.doi.org/10.1177/2053369117705058.

30. Wilson S.A., Stem L.A., Bruehlman R.D. Hypothyroidism: Diagnosis and treatment. Am Fam Physician. 2021; 103(10): 605–13.

31. Качук Ю.В. Поражение кожи при нарушениях функции щитовидной железы. Дерматовенерология. Косметология. Сексопатология. 2013; 1: 228–232. [Kachuk Yu.V. Damage in case of dysfunction of the thyroid gland. Dermatovenerologiya. Kosmetologiya. Seksopatologiya. 2013; 1: 228–232 (In Russ.)].

32. Бабенко А.Ю., Гринева Е.Н., Солнцев В.Н. Фибрилляция предсердий при тиреотоксикозе – детерминанты развития и сохранения. Клиническая и экспериментальная тиреодология. 2013; 9(1): 29–37. [Babenko A.Yu., Grineva E.N., Solntsev V.N. Atrial fibrillation in thyrotoxicosis – determinants of development and maintenance. Klinicheskaya i eksperimental'naya tireodologiya = Clinical and Experimental Thyroidology. 2013; 9(1): 29–37 (In Russ.)]. EDN: RSYZZF.

33. Mancino G., Miro C., Di Cicco E., Dentice M. Thyroid hormone action in epidermal development and homeostasis and its implications in the pathophysiology of the skin. J Endocrinol Invest. 2021; 44(8): 1571–79. https://dx.doi.org/10.1007/s40618-020-01492-2.

34. Song X., Shen Y., Zhou Y. et al. General hyperpigmentation induced by Grave’s disease: A case report. Medicine (Baltimore). 2018; 97(49): e13279. https://dx.doi.org/10.1097/MD.0000000000013279.

35. Сабанова Е.А., Фадеев В.В., Потекаев Н.Н., Львов А.Н. Претибиальная микседема: патогенетические особенности и клинические аспекты. Проблемы эндокринологии. 2019; 65(2): 134–138. [Sabanova E.A., Fadeyev V.V., Potekaev N.N., Lvov A.N. Pretibial myxedema: pathogenetic features and clinical aspects. Problemy endocrinologii = Problems of Endocrinology. 2019; 65(2): 134–138 (In Russ.)]. https://dx.doi.org/10.14341/probl9848. EDN: ORLMQS.

36. Lause M., Kamboj A., Fernandez Faith E. Dermatologic manifestations of endocrine disorders. Transl Pediatr. 2017; 6(4): 300–12. https://dx.doi.org/10.21037/tp.2017.09.08.

37. Malan M., Dai Z., Jianbo W., Quan S.J. Onycholysis an early indicator of thyroid disease. Pan Afr Med J. 2019; 32: 31. https://dx.doi.org/10.11604/pamj.2019.32.31.17653.

38. Buliman A., Tataranu L.G., Paun D.L. et al. Cushing’s disease: A multidisciplinary overview of the clinical features, diagnosis, and treatment. J Med Life. 2016; 9(1): 12–18.

39. Stratakis C.A. Skin manifestations of Cushing’s syndrome. Rev Endocr Metab Disord. 2016; 17(3): 283–86. https://dx.doi.org/10.1007/s11154-016-9399-3.

40. Senanayake R., Gillett D., MacFarlane J. et al. New types of localization methods for adrenocorticotropic hormone-dependent Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab. 2021; 35(1): 101513. https://dx.doi.org/10.1016/j.beem.2021.101513.

41. Панькив В.И. Первичная недостаточность коры надпочечников. Международный эндокринологический журнал. 2013; 3: 110–118. [Pankiv V.I. Primary adrenal insufficiency. Mezhdunarodnyy endokrinologicheskiy zhurnal = International Journal of Endocrinology. 2013; 3: 110–118 (In Russ.)]. EDN: QYOBJP.

42. Панькив В.И. Недостаточность минералокортикоидов: этиология, патогенез, диагностика, подходы к лечению. Международный эндокринологический журнал. 2012; 1: 107–119. [Pankiv V.I. Mineralocorticoid deficiency: Etiology, pathogenesis, diagnosis, treatment approaches. Mezhdunarodnyy endokrinologicheskiy zhurnal = International Journal of Endocrinology. 2012; 1: 107–119 (In Russ.)]. EDN: RAGOMF.

43. Молашенко Н.В., Сазонова А.И., Трошина Е.А. Врожденная дисфункция коры надпочечников у взрослых пациентов: алгоритм диагностики и лечения. Consilium Medicum. 2017; 19(4): 70–74. [Molashenko N.V., Sazonova A.I., Troshina E.A. Congenital dysfunction of the adrenal cortex in adult patients: an algorithm for diagnosis and treatment. Consilium Medicum. 2017; 19(4): 70–74 (In Russ.)]. EDN: ZGFANF.

44. Бирюкова Е.В., Ганенкова Е.С., Лованова М.Д. Хроническая надпочечниковая недостаточность в практике клинициста. Consilium Medicum. 2019; 21(4): 103–108. [Biryukova E.V., Ganenkova E.S., Lovanova M.D. Chronic adrenal insufficiency in clinical practice. Consilium Medicum. 2019; 21(4): 103–108 (In Russ.)]. https://dx.doi.org/10.26442/20751753.2019.4.190311. EDN: TZEWWL.

45. Fasano A., Leonard M.M., Mitchell D.M., Eng G. Case 1-2020: An 11-year-old boy with vomiting and weight loss. N Engl J Med. 2020; 382(2): 180–89. https://dx.doi.org/10.1056/NEJMcpc1913469.

46. de Silva T., Cosentino G., Ganji S. et al. Endocrine causes of hypertension. Curr Hypertens Rep. 2020; 22(11): 97. https://dx.doi.org/10.1007/s11906-020-01108-3.

47. Boix J., Bigas J., Sevilla L.M. et al. Primary aldosteronism patients show skin alterations and abnormal activation of glucocorticoid receptor in keratinocytes. Sci Rep. 2017; 7(1): 15806. https://dx.doi.org/10.1038/s41598-017-16216-5.

48. Zhang H., Miao C., Zhang X. Hyperkeratosis lenticularis perstans in a patient with primary hyperaldosteronism. J Dtsch Dermatol Ges. 2018; 16(1): 72–73. https://dx.doi.org/10.1111/ddg.13392.

49. Ben-Shlomo A., Melmed S. Skin manifestations in acromegaly. Clin Dermatol. 2006; 24(4): 256–59. https://dx.doi.org/10.1016/j.clindermatol.2006.04.011.

50. Degirmentepe E.N., Gungor S., Kocaturk E. et al. Dermatologic manifestations of acromegaly: A case in point and a focused review. Dermatol Online J. 2017; 23(8): 13030/qt50s903qh.

51. Demirkesen C. Skin manifestations of endocrine diseases. Turk Patoloji Derg. 2015; 31(1): 145–54. https://dx.doi.org/10.5146/tjpath.2015.01321.

52. Дедов И.И., Мельниченко Г.А., Мокрышева Н.Г. с соавт. Первичный гиперпаратиреоз: клиника, диагностика, дифференциальная диагностика, методы лечения. Проблемы эндокринологии. 2016; 62(6): 40–77. [Dedov I.I., Melnichenko G.A., Mokrysheva N.G. et al. Primary hyperparathyroidism: the clinical picture, diagnostics, differential diagnostics, and methods of treatment. Problemy endokrinologii = Problems of Endocrinology. 2016; 62(6): 40–77 (In Russ.)]. https://dx.doi.org/10.14341/probl201662640-77. EDN: XIAIZZ.

53. Еремкина А.К., Ковалева Е.В. Гипопаратиреоз: этиология, клиническая картина, современные методы диагностики и лечения. Альманах клинической медицины. 2016; 44(4): 477–492. [Eremkina A.K., Kovaleva E.V. Hypoparathyroidism: etiology, clinical presentation, modern methods of diagnosis and treatment. Al’manah klinicheskoy meditsiny = Almanac of Clinical Medicine. 2016; 44(4): 477–492 (In Russ.)]. https://dx.doi.org/10.18786/2072-0505-2016-44-4-477-492. EDN: XDMMFJ.

54. Гребенникова Т.А., Белая Ж.Е., Мельниченко Г.А. Гипопаратиреоз: современное представление о заболевании и новые методы лечения. Эндокринная хирургия. 2017; 11(2): 70–80. [Grebennikova T.A., Belaya Zh.E., Melnichenko G.A. Hypoparathyroidism: disease update and new methods of treatment. Endokrinnaya khirurgiya = Endocrine Surgery. 2017; 11(2): 70–80 (In Russ.)]. https://dx.doi.org/10.14341/serg2017270-80. EDN: ZIWQSP.

55. Jabbour S.A. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol. 2003; 4(5): 315–31. https://dx.doi.org/10.2165/00128071-200304050-00003.

56. Kahaly G.J., Zimmermann J., Hansen M.P. et al. [Endocrinology and interdisciplinary consultation in internal medicine: Illustrated using the example of polyglandular autoimmune syndrome]. Internist (Berl). 2017; 58(4): 308–28 (In German)]. https://dx.doi.org/10.1007/s00108-017-0201-8.

57. Паневин Т.С., Молашенко Н.В., Трошина Е.А., Головенко Е.Н. Аутоиммунный полигландулярный синдром взрослых: современные представления о предикторах развития поражения миокарда и диагностике компонентов заболевания. Клиническая и экспериментальная тиреоидология. 2018; 14(2): 92–99. [Panevin T.S., Molashenko N.V., Troshina E.A., Golovenko E.N. Autoimmune polyglandular syndrome of adults: current ideas about predictors development of damage of a myocardium and diagnostics of components of a disease. Klinicheskaya i eksperimental’naya tireoidologiya = Clinical and Experimental Thyroidology. 2018; 14(2): 92–99 (In Russ.)]. https://dx.doi.org/10.14341/ket9641. EDN: XWQWTZ.

58. Horino T., Ogasawara M., Ichii O., Terada Y. Autoimmune polyglandular syndrome type 3 variant in rheumatoid arthritis. Rom J Intern Med. 2020; 58(1): 40–43. https://dx.doi.org/10.2478/rjim-2019-0024.

59. Keen M.A., Shah I.H., Sheikh G. Cutaneous manifestations of polycystic ovary syndrome: A cross-sectional clinical study. Indian Dermatol Online J. 2017; 8(2): 104–10. https://dx.doi.org/10.4103/2229-5178.202275

60. Sharma Y.K., Chauhan S., Singh P., Deo K. Correlation of cutaneous manifestations with body mass index, blood glucose, and hormonal levels in patients with polycystic ovarian disease. Indian Dermatol Online J. 2020; 11(3): 378–81. https://dx.doi.org/10.4103/idoj.IDOJ_193_18.

61. Uzuncakmak T.K., Akdeniz N., Karadag A.S. Cutaneous manifestations of obesity and the metabolic syndrome. Clin Dermatol. 2018; 36(1): 81–88. https://dx.doi.org/10.1016/j.clindermatol.2017.09.014.

62. Hirt P.A., Castillo D.E., Yosipovitch G., Keri J.E. Skin changes in the obese patient. J Am Acad Dermatol. 2019; 81(5): 1037–57. https://dx.doi.org/10.1016/j.jaad.2018.12.070.